3 research outputs found
Prediction of Breast Cancer Proteins Involved in Immunotherapy, Metastasis, and RNA-Binding Using Molecular Descriptors and Artifcial Neural Networks
[Abstract]
Breast cancer (BC) is a heterogeneous disease where genomic alterations, protein expression
deregulation, signaling pathway alterations, hormone disruption, ethnicity and environmental
determinants are involved. Due to the complexity of BC, the prediction of proteins involved in this
disease is a trending topic in drug design. This work is proposing accurate prediction classifer for BC
proteins using six sets of protein sequence descriptors and 13 machine-learning methods. After using
a univariate feature selection for the mix of fve descriptor families, the best classifer was obtained
using multilayer perceptron method (artifcial neural network) and 300 features. The performance
of the model is demonstrated by the area under the receiver operating characteristics (AUROC) of
0.980±0.0037, and accuracy of 0.936±0.0056 (3-fold cross-validation). Regarding the prediction of
4,504 cancer-associated proteins using this model, the best ranked cancer immunotherapy proteins
related to BC were RPS27, SUPT4H1, CLPSL2, POLR2K, RPL38, AKT3, CDK3, RPS20, RASL11A and
UBTD1; the best ranked metastasis driver proteins related to BC were S100A9, DDA1, TXN, PRNP,
RPS27, S100A14, S100A7, MAPK1, AGR3 and NDUFA13; and the best ranked RNA-binding proteins
related to BC were S100A9, TXN, RPS27L, RPS27, RPS27A, RPL38, MRPL54, PPAN, RPS20 and CSRP1.
This powerful model predicts several BC-related proteins that should be deeply studied to fnd new
biomarkers and better therapeutic targets. Scripts can be downloaded at https://github.com/muntisa/
neural-networks-for-breast-cancer-proteins.This work was supported by a) Universidad UTE (Ecuador), b) the Collaborative Project in Genomic Data Integration (CICLOGEN) PI17/01826 funded by the Carlos III Health Institute from the Spanish National plan for Scientific and Technical Research and Innovation 2013-2016 and the European Regional Development Funds (FEDER) - “A way to build Europe”; c) the General Directorate of Culture, Education and University Management of Xunta de Galicia ED431D 2017/16 and “Drug Discovery Galician Network” Ref. ED431G/01 and the “Galician Network for Colorectal Cancer Research” (Ref. ED431D 2017/23); d) the Spanish Ministry of Economy and Competitiveness for its support through the funding of the unique installation BIOCAI (UNLC08-1E-002, UNLC13-13-3503) and the European Regional Development Funds (FEDER) by the European Union; e) the Consolidation and Structuring of Competitive Research Units - Competitive Reference Groups (ED431C 2018/49), funded by the Ministry of Education, University and Vocational Training of the Xunta de Galicia endowed with EU FEDER funds; f) research grants from Ministry of Economy and Competitiveness, MINECO, Spain (FEDER CTQ2016-74881-P), Basque government (IT1045-16), and kind support of Ikerbasque, Basque Foundation for Science; and, g) Sociedad Latinoamericana de Farmacogenómica y Medicina Personalizada (SOLFAGEM)Xunta de Galicia; ED431D 2017/16Xunta de Galicia; ED431G/01Xunta de Galicia; ED431D 2017/23Xunta de Galicia; ED431C 2018/49Gobierno Vasco; IT1045-1
Markovian chemical in silico design (MARCH-INSIDE), a promising approach for computer-aided molecular design I: discovery of anticancer compounds
A simple stochastic approach, designed to model the movement of electrons throughout chemical bonds, is introduced. This model makes use of a Markov matrix to codify useful structural information in QSAR. The self-return probabilities of this matrix throughout time (SRpgrk) are then used as molecular descriptors. Firstly, a calculation of SRpgrk is made for a large series of anticancer and non-anticancer chemicals. Then, k-Means Cluster Analysis allows us to split the data series into clusters and ensure a representative design of training and predicting series. Next, we develop a classification function through Linear Discriminant Analysis (LDA). This QSAR discriminates between anticancer compounds and non-active compounds with a correct global classification of 90.5% in the training series. The model also correctly classified 86.07% of the compounds in the predicting series. This classification function is then used to perform a virtual screening of a combinatorial library of coumarins. In this connection, the biological assay of some furocoumarins, selected by virtual screening using the present model, gives good results. In particular, a tetracyclic derivative of 5-methoxypsoralen (5-MOP) has an IC50 against HL-60 tumoral line around 6 to 10 times lower than those for 8-MOP and 5-MOP (reference drugs), respectively. Finally, application of Iso-contribution Zone Analysis (IZA) provides structural interpretation of the biological activity predicted with this QSAR